The "Global Kidney Cancer and Renal Cell Carcinoma Drugs Market" size was worth US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2022-2029).
Kidney Cancer and Renal Cell Carcinoma, are also known as kidney cancer, is a type of cancer that begins with kidney cells. The two types of kidney cancer are transitional cell carcinoma (TCC) and renal cell carcinoma (RCC). These names depict the type of cell from which cancer originated. Most people with renal cell carcinoma are adults, usually between ages 50 and 70. Different types of kidney cancer (like RCC and TCC) develop differently, which means that diseases have different long-term outcomes and should be controlled and treated differently. RCC accounts for about 80% of primary kidney cancers, and TCC accounts for most rest. Some symptoms are anemia, losing weight, low back pain, A lump on the side, belly. Mainly caused due to smoking, taking many pain medicines for a longer time, Having Hepatitis C. The market is expected to drive in the future due to the high prevalence rate of Kidney Cancer and Renal Cell Carcinoma cases.
Source: DataM Intelligence Analysis (2020)
The global Kidney Cancer and Renal Cell Carcinoma Drugs market growth is driven by the growing incidence of Kidney cancers and RCC cases, and due to unhealthy lifestyle like obesity, smoking, increasing geriatric population. Moreover, strong pipeline drugs are the major factors driving the market.
Increasing incidence of Kidney Cancers & RCC cases, is expected to drive the global Kidney Cancer and Renal Cell Carcinoma Drugs market during the forecast period.
Kidney cancer & Renal Cell Carcinoma (RCC) are the 10th most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 80 (1.03%). As per the American Cancer Society’s most recent estimates for kidney cancer in the United States for 2021 are: About 76,080 new cases of kidney cancer (48,780 in men and 27,300 in women) will be diagnosed. RCC accounts for about 80% of primary kidney cancers, and Metastatic RCC is present in around 30.0% of patients at the time of diagnosis. These factors are driving the growth of the market in the forecast period.
Strong pipeline of drugs, is expected to drive the global Kidney Cancer and Renal Cell Carcinoma Drugs market during the forecast period.
Strong pipeline drugs like Swiss Group for Clinical Cancer Research- Immunotherapy with checkpoint inhibitors that target PD-1 and CTLA-4 have shown activity in mRCC are nivolumab, ipilimumab under Phase 2 trial.
MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple-negative breast cancer (TNBC) and combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC) are expected to drive the global Kidney Cancer and Renal Cell Carcinoma Drugs market during the forecast period.
Major side effects of drugs is likely to hinder the market growth
On the contrary, side effects related to Angiogenesis Inhibitors and mTOR Inhibitors such as rapid heart rate, and high blood sugar are likely to hamper the overall demand for Kidney Cancer and Renal Cell Carcinoma Drugs market.
According to the American Cancer Society, reported that patients who took these drugs having side effects for Angiogenesis Inhibitors: The most common side effects are nausea, diarrhea, changes in skin or hair color, mouth sores, weakness, and low white and red blood cell counts. Other dangerous effects include tiredness, high blood pressure, congestive heart failure, bleeding, hand-foot syndrome, and low thyroid hormone levels.
mTOR Inhibitors: This drug's most common side effects include mouth sores, an increased risk of infections, nausea, loss of appetite, diarrhea, skin rash, feeling tired or weak, edema, and high blood sugar and cholesterol levels. A less common but dangerous side effect is lung damage, which can cause shortness of breath or other problems.
COVID-19 Impact Analysis
Due to the covid-19 pandemic outbreak, the market for Global Kidney Cancer and Renal Cell Carcinoma Drugs Market was seen to be down, due to the barriers in production and sales segments. Since the outbreak led to the shutdown of all manufacturing firms except for masks, sanitizers and ventilators. Hence, the Drugs were manufactured less compared to previous years, during the outbreak.
Based on the Product Type, the global Kidney Cancer and Renal Cell Carcinoma Drugs market is segmented into Afinitor (Everolimus), Avastin (Bevacizumab), Cabomety (Cabozantinib), Inlyta (Axitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), Sutent (Sunitinib), Votrient (Pazopanib).
Bevacizumab (avastin) drug, accounts largest share in the global Kidney Cancer and Renal Cell Carcinoma Drugs market.
It works similarly to Rapamycin (sirolimus) as an mTOR (mammalian target of Rapamycin) inhibitor, and it is currently used as an immunosuppressant to prevent organ rejection transplants in advanced kidney cancer patients.
It gained FDA approval in 2004 for specific cancer types and became the first angiogenic inhibitor introduced to the market. Bevacizumab is a humanized monoclonal IgG antibody and inhibits angiogenesis by binding and neutralizing VEGF-A and is generally indicated for use in combination with different chemotherapy regimens specific to the type, severity, and IV stage of kidney cancer.
Avastin sold 7.07 billion Swiss francs ($7.46 billion) around the world in 2019. Among them, one-fourth, or 1.79 billion Swiss franc sales, came from Europe.
In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.
Is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. The FDA approved temsirolimus in late May 2007 and the European Medicines Agency (EMEA) in November 2007.
It is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
It is a second-generation tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) used to treat advanced kidney cancer through this mechanism of action, axitinib blocks angiogenesis, tumor growth and metastases. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
It is marketed as Nexavar by Bayer, it is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer) and It is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor.
It is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, it was approved by the US FDA for the indications of treating renal cell carcinoma (RCC). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs which include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).
Based on Distribution channel, the hospital pharmacy are expected to dominate the Global Kidney Cancer and Renal Cell Carcinoma Drugs market during the forecast period
The hospital pharmacies held the largest share in the global Kidney Cancer and Renal Cell Carcinoma Drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Source: DataM Intelligence Analysis (2020)
North America served the largest share of the market due to the increasing prevalence of urological cancer diseases. According to the American Cancer Society’s estimates for the number of colorectal cancer cases in the United States for 2021 are: About 76,080 new cases of kidney cancer (48,780 in men and 27,300 in women). The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing oncology products.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, the Ongoing Healthy China 2020 healthcare reform and the removal of price caps on all medicine categories. The Chinese government has initiated a supportive 12th Five-Year Plan measures targeting biotechnology as a crucial development sector. Additionally, a large target base with unmet solid clinical needs is expected to drive regional market growth.
Source: DataM Intelligence Analysis (2020)
The Global Kidney Cancer & Renal Cell Carcinoma Drugs Market is quite competitive with some key competitors like Active Biotech Ab, Amgen, Bayer AG, Roche Holding AG, Glaxosmithkline Plc, Novartis AG, Heidelberg Pharma AG, Inc, Bristol-Myers Squibb, Eisai, Exelixis. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, A multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
Renal Cell Carcinoma
Drug: 124-Iodine-cG250 (124I-cG250)
Heidelberg Pharma AG
Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With our combined strength in pharmaceuticals and diagnostics, we are better equipped than any other company to drive personalized healthcare further. Two-thirds of our Research and Development projects are being developed with companion diagnostics.
Product Portfolio: The company portfolio includes Oncology, Neurology, Endocrinology, Infectious diseases and others.
Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death-ligand 1) aiming to prevent cancer immune evasion and A phase III clinical trial drug for the treatment of adjuvant renal cell carcinoma.
The global Kidney Cancer & Renal Cell Carcinoma Drugs report would provide an access to an approx. 53 market data table, 48 figures and 180 pages.
Get your free sample proposal with a single click!